NASDAQ:ZEAL - ZEALAND PHARMA/S Price Target & Analyst Ratings

Sign in or create an account to add this stock to your watchlist.
$20.14 +0.05 (+0.25 %)
(As of 04/26/2019 09:43 AM ET)
Previous Close$20.09
Today's Range$20.14 - $20.14
52-Week Range$11.51 - $20.00
Volume19,654 shs
Average Volume11,699 shs
Market Capitalization$620.11 million
P/E Ratio6.71
Dividend YieldN/A
Beta2.26

Analyst Ratings

ZEALAND PHARMA/S (NASDAQ:ZEAL) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
3 Wall Street analysts have issued ratings and price targets for ZEALAND PHARMA/S in the last 12 months. Their average twelve-month price target is $29.00, suggesting that the stock has a possible upside of 43.99%. The high price target for ZEAL is $29.00 and the low price target for ZEAL is $29.00. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.672.672.673.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $29.00$29.00$29.00$29.00
Price Target Upside: 43.99% upside96.48% upside124.13% upside56.84% upside

ZEALAND PHARMA/S (NASDAQ:ZEAL) Consensus Price Target History

Price Target History for ZEALAND PHARMA/S (NASDAQ:ZEAL)

ZEALAND PHARMA/S (NASDAQ:ZEAL) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/7/2019Needham & Company LLCReiterated RatingBuy$29.00MediumView Rating Details
12/17/2018Goldman Sachs GroupDowngradeBuy ➝ NeutralMediumView Rating Details
9/12/2018Morgan StanleySet Price TargetBuy$29.00HighView Rating Details
9/5/2017GuggenheimInitiated CoverageBuy ➝ Buy$28.00HighView Rating Details
(Data available from 4/26/2017 forward)
This page was last updated on 4/26/2019 by MarketBeat.com Staff

Featured Article: Growth and Income Funds

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel